Vaxcyte Inc Stock News

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “not...

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under...

Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete with Pfizer's Prevnar 20 and Merck's Capvaxive in the adult pneumococcal vaccine market, which Jefferie...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.

Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer